Stay updated on Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Sign up to get notified when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.

Latest updates to the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRecruitment status now indicates no longer looking for participants, and new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) are added. The Intervention / Treatment heading was renamed to Intervention/Treatment and the revision version updated to v3.6.0.SummaryDifference0.5%

- Check18 days agoChange DetectedRevision label updated to v3.5.5, reflecting a minor update to the page's documentation/template.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page's revision tag has been updated to v3.5.4. The previous revision tag v3.5.3 was removed.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page’s display version/revision indicator was updated from v3.5.0 to v3.5.3, reflecting a site/release stack change rather than any modification to the underlying study information.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded detailed definitions for response criteria (iRECIST/RECIST) and endpoints (CR, PR, SD, PD) under Outcome Measures. Included an external resource reference (Genetic and Rare Diseases Information Center) related to head and neck cancer terminology.SummaryDifference0.8%

- Check97 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-visible changes to the Study Details page are indicated.SummaryDifference0.1%

Stay in the know with updates to Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radiotherapy and Pembrolizumab in Metastatic HNSCC Clinical Trial page.